Business Context and Reporting Period
Company: Ultragenyx Pharmaceutical Inc. (RARE)
Filing Type: Form 8-K (Current Report)
Date of Report: October 30, 2025
Event: Announcement of the first patient dosed in the Aurora study (NCT07157254) for GTX-102 (apazunersen) to treat Angelman syndrome (AS).
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a clinical development milestone. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. Investors should refer to the Company's Quarterly Report on Form 10-Q filed on August 6, 2025, for financial metrics.
Material Changes and Clinical Updates
- Aurora Study Initiation: First patient dosed on October 30, 2025. The study evaluates GTX-102 in a broader population than the Phase 3 Aspire study, including ages 1 to <65 and various AS genotypes.
- Study Design: Approximately 60 participants across four cohorts:
- Cohort A: Ages 1 to <4, Deletion-type AS (Primary Endpoint: Bayley-4 cognitive raw score).
- Cohort B: Ages 4 to <18, UPD and ICD genotypes (Primary Endpoint: MDRI response).
- Cohort C: Ages 18 to <65, All genotypes (Primary Endpoint: MDRI response).
- Cohort D: Ages 4 to <18, UBE3A gene mutation (Randomized 2:1 to GTX-102 or No Treatment; Primary Endpoint: MDRI response).
- Aspire Study Status: The fully enrolled Phase 3 Aspire study (NCT06617429) completed enrollment in July 2025 ahead of plan with 129 participants (ages 4-17, deletion-type AS) across 28 global sites.
- Data Expectations: Data from the Aspire study are expected in the second half of 2026.
Guidance, Outlook, and Risks
Outlook: Management anticipates data readouts from the Aspire study in H2 2026. The Aurora study aims to expand the treated population to include younger, older, and non-deletion genotype patients.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include:
- Uncertainty of clinical drug development and regulatory approval processes.
- Potential for adverse side effects or lack of efficacy.
- Reliance on third-party partners.
- Manufacturing risks and competition.
- Sufficiency of existing cash to fund operations.
Investor Verification Checklist
- Verify the enrollment progress and safety data from the Aurora study as it moves beyond the first patient.
- Monitor the timeline for the Aspire study data readout expected in the second half of 2026.
- Review the most recent Form 10-Q (filed August 6, 2025) for current cash runway and burn rate, as this 8-K does not provide financial figures.
- Assess the regulatory pathway for GTX-102 given the inclusion of multiple genotypes and age groups in the Aurora study.